[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fvkMaJ5bERMQf48VeMJOEiTgS3g-x1UkugbJbD2sOWIo":8,"$f0s1Up70sLQteXeWxAqOOBA4o8VT9qtbr7bQ9TYHLVTs":55,"$foN_J8NqTD1kWW8QhBe-OIHSFsXN0UcxGEW1wYf3U2QU":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},50330,868724,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//584jzwZ4DkodQ6yfnGDMA9fIjTGDs9LC.png","张溪","山西省肿瘤医院","肿瘤内科","主治医师",12,0,"食管腺癌相关药品用药安全全解 💊🛡️","","https://ystcdn.venuertc.com/venue/AI/dd54a185-9f54-4ce9-986c-5275ffc6a995.jpg","\u003Cdiv class=\"esophaguide-wrap\">\n  \u003Ch1 id=\"material_title\" class=\"esophaguide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">食管腺癌相关药品用药安全全解  \u003Cspan class=\"esophaguide-emoji\">💊🛡️\u003C/span>\u003C/h1>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background-color:#f7faff;padding:36px 28px 18px 28px;border-radius:18px;margin-bottom:28px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🔷\u003C/span> 药物基础知识 —— 走进食管腺癌治疗常用药\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">说起来，帮助食管腺癌治疗的药品种类相当丰富。我们最常接触到的是化疗药、靶向治疗药物和免疫检查点抑制剂（如信迪利单抗）。这些药物大多属于注射剂型，需要在医院专科指导下使用。本文将为你梳理7大用药安全细节，每一点都和实际用药息息相关。\u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(120deg,#f6f7fb 90%,#e3f6fd 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🕰️\u003C/span> 01. 免疫检查点抑制剂（如信迪利单抗）的使用时机与给药方法\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n    \u003Cb>类别说明：\u003C/b>信迪利单抗属于\u003Cstrong>PD-1抑制剂\u003C/strong>，用作食管腺癌治疗方案中的免疫治疗环节。其主要成分为全人源化单克隆抗体，通过阻断PD-1通路，激活自身体内T细胞抵抗癌细胞。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>正确用法：\u003C/b>通常以每次200mg剂量，\u003Cu>静脉输注\u003C/u>，间隔3周一次。每次输注时间需控制在30-60分钟，严格遵医嘱操作，不可自行调节速度。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">⚠️\u003C/span> 用法小贴士：免疫治疗多需配合血氧、心电等动态监测，首次输注时尤为重要。遇有不适症状应立即告知医护。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(135deg, #fcfcf7 80%, #e7f7ef 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">💉\u003C/span> 02. 化疗药物的剂型、给药技巧及常见问题\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      化疗药物（如紫杉醇、多西他赛、奥沙利铂等）大多为静脉输注剂型。每种化疗方案的剂量严格按体表面积计算，不能随个人体重擅自改动。部分药物对胃肠道、骨髓抑制作用较大，用药间隔需遵医嘱。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n    \u003Cb>服用前建议：\u003C/b>部分化疗药品需与止吐药（如昂丹司琼）合用，提前至少半小时用药。出现口腔溃疡、脱发等反应不必恐慌，多为可逆现象。如明显白细胞下降，务必告知医师。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">📝\u003C/span> 正确做法：每次化疗前测血常规、肝肾功能，并确保无严重感染或其它用药禁忌。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(110deg,#f6f8fc 80%,#f2fafa 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🎯\u003C/span> 03. 靶向治疗药：剂量、联合规律与原理\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      靶向药（如曲妥珠单抗）主要针对HER-2表达阳性的肿瘤组织，利用抗体与细胞表面靶点结合，精准阻断肿瘤细胞信号通路，抑制增殖。曲妥珠单抗一般采用静脉滴注，每次用药时间约90分钟，后续可缩短至30分钟。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>联合用药原则：\u003C/b>常与化疗药（如紫杉醇、顺铂等）合用，注意联合用药时的剂量及先后顺序，不可混在同一瓶内。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">🔥\u003C/span> 特别提醒：靶向药物使用期间需监测心功能，若有心悸或气促，应暂停用药进一步评估。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(110deg,#f7fcfa 70%,#eef6ff 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🌟\u003C/span> 04. 药物相互作用与联合禁忌\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      化疗及免疫、靶向药联用时需关注：\n      \u003C/p>\u003Cul class=\"esophaguide-list\">\n        \u003Cli>免疫抑制剂（如激素类药物）大量合用会降低免疫治疗药效。\u003C/li>\n        \u003Cli>卡马西平、苯妥英等肝脏酶诱导剂与部分化疗/靶向药合用，可能加快药物代谢，降低疗效。\u003C/li>\n        \u003Cli>抗生素、抗真菌类药（如氟康唑）与化疗药并用时，肝毒性、白细胞减少风险增加。\u003C/li>\n      \u003C/ul>\n    \u003Cp>\u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>正确做法：\u003C/b>合用药品前请主动向医生报告当前和近期所有用药清单。遇到处方调整，需再次核对有无药物互相干扰的风险。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">🔒\u003C/span> 需要注意：不以“补药”“保健品”身份擅自叠加服用，特别是含有维生素A、E等成分的自购制剂。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(135deg,#f4faf7 90%,#f5f6fc 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">👵🏼\u003C/span> 05. 特殊人群（老年、肝肾损害等）剂量和监测要点\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      对于老年患者，部分药品的剂量可能需适当下调。例如，化疗药或免疫药在体重指数偏高、肝肾功能有异常时，都要由医师评估后定制给药计划。肝损害或肾损害时，一些药物（如奥沙利铂、卡铂等）代谢排泄减慢，积聚风险更大。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>监测要点：\u003C/b>每个周期治疗期间定期复查肝功能、肾功能、血象、电解质，发现指标异常应暂缓用药并调整治疗。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">🆘\u003C/span> 特别提醒：老年患者更易受药物毒性影响，初次服药剂量勿超常规范围，不适感出现应立即就医。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(110deg,#f4f7fd 70%,#f9faf7 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🚩\u003C/span> 06. 主要不良反应、应对和处理经验\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>化疗药常见不良反应：\u003C/b>白细胞、血小板下降，恶心、呕吐、脱发。免疫药（如信迪利单抗）：发热、皮疹、乏力为主，少见但重要的有免疫相关肺炎、肝炎、甲状腺功能异常。靶向药（如曲妥珠单抗）：心功能受影响、胃肠道反应。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>正确做法：\u003C/b>主动监测体温、皮肤和呼吸变化，每周自查口腔、皮肤、体重。如遇持续高烧、呼吸急促、皮肤发红、关节肌肉痛或黄疸，需及时就诊。可轻度的口腔溃疡、脱发一般是可逆的，多补充营养、避免刺激即可耐受。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">💡\u003C/span> 免疫治疗后的严重反应如免疫性肺炎或肝炎，遇有症状需紧急停药、就医。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(130deg,#fdfbf7 80%,#e2f6fa 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🧊\u003C/span> 07. 储存方法与药物处理\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>存放细节：\u003C/b>注射制剂应贮存在2-8℃冰箱冷藏（不能冷冻），原包装避光密封，勿长期暴露室温，且防潮防震。一旦稀释后未及时用完要根据说明书严格限制使用时限，剩余药物不可自行带回家或再次使用。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>过期处理：\u003C/b>药品过期后应交由医院或正规药店回收，不可自行丢弃进垃圾桶，以免产生药害环境。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">🧾\u003C/span> 家庭无特殊贮存条件时，禁止储存任何针剂类药物。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(110deg, #f7fcfa 70%, #f3f6fd 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">🔍\u003C/span> 08. 漏服与过量用药后的应对\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>漏服情况：\u003C/b>静脉用药基本由专科医护完成，偶有延迟建议由医师重新安排时间，切勿自行为了“补齐进度”自行加量。口服辅助药（如止吐药）漏服及时补服一次即可，不可短时连续加倍。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-text\">\n      \u003Cb>过量风险：\u003C/b>注射制剂使用超量，可能导致严重骨髓抑制、严重免疫副反应等。务必向医护如实报告，按医生指示接受对应支持和解毒治疗。口服药过量则要密切观察并可考虑洗胃、活性炭等措施，最快时间送医。\n    \u003C/p>\n    \u003Cp class=\"esophaguide-tip\">\n      \u003Cspan class=\"esophaguide-emoji\">🚑\u003C/span> 任何超量风险都应立即就诊，不要自己处理。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-example-wrap\">\n    \u003Ch3 class=\"esophaguide-example-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">📚\u003C/span> 临床用药实际简例\u003C/h3>\n    \u003Cul class=\"esophaguide-list\">\n      \u003Cli>有位60岁男性患者静脉输注信迪利单抗200mg，监测3小时无不良反应。用药全程严控输注速率与配套监护。\u003C/li>\n      \u003Cli>临床上使用曲妥珠单抗联合紫杉醇治疗HER-2表达阳性患者时，需专门安排心电图和肝肾功能检测，避免心脏损害。\u003C/li>\n      \u003Cli>化疗药给药期间曾有患者出现白细胞下降，及时调整剂量及延长疗程，顺利恢复血象。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-section\" style=\"background:linear-gradient(115deg,#f7faff 90%,#e4f6d7 100%);padding:32px 25px 12px 25px;border-radius:18px;margin-bottom:26px;\">\n    \u003Ch2 class=\"esophaguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"esophaguide-emoji\">📝\u003C/span> 结语：安全用药，疗效加倍\u003C/h2>\n    \u003Cp class=\"esophaguide-text\">\n    合理使用免疫、化疗和靶向药，是提升治疗效果的基础。每一次给药都离不开医生与家属的紧密配合，患者自身细微不适也不能放松警惕。请牢记：合理告知用药史，严格尊循每一剂量、每一种用药规定，是保护自身健康、规避风险的核心。如遇疑问，请及时咨询专业医师和药师支持。\u003C/p>\n    \u003Cp class=\"esophaguide-text\" style=\"color:#497746;font-weight:bold;\">\n    药物本无情，知其性、用其道，方可善其终。安全用药，每一天都很重要！\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"esophaguide-ref-section\">\n    \u003Ch4 class=\"esophaguide-ref-title\">References\u003C/h4>\n    \u003Col class=\"esophaguide-ref-list\">\n      \u003Cli>Xu, J., Zhang, Y., Cheng, Y., et al. (2020). Sintilimab plus chemotherapy vs. chemotherapy in advanced esophageal squamous cell carcinoma: results of a randomized, double-blind, phase 3 trial. \u003Ci>Journal of Clinical Oncology\u003C/i>, 38(35), 4176–4186. https://doi.org/10.1200/JCO.20.01891\u003C/li>\n      \u003Cli>Bang, Y. J., Van Cutsem, E., Feyereislova, A., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. \u003Ci>Lancet\u003C/i>, 376(9742), 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X\u003C/li>\n      \u003Cli>Kato, K., Sun, J. M., Shah, M. A., et al. (2019). Pembrolizumab versus chemotherapy in advanced esophageal cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 382(2), 161-172. https://doi.org/10.1056/NEJMoa1915908\u003C/li>\n      \u003Cli>Ford, H. E., Marshall, A., Bridgewater, J. A., et al. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, randomised phase 3 trial. \u003Ci>Lancet Oncology\u003C/i>, 15(1), 78-86. https://doi.org/10.1016/S1470-2045(13)70549-7\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\u003Cstyle>\n.esophaguide-wrap {\n  font-family: \"Segoe UI\", Tahoma, Geneva, Verdana, sans-serif;\n  background-color: #f5f6fa;\n  color: #32374d;\n  max-width: 820px;\n  margin: 0 auto;\n  padding-bottom: 36px;\n}\n.esophaguide-title {\n  text-align: center;\n  font-size: 2.3rem;\n  font-weight: 700;\n  letter-spacing: 0.03em;\n  margin: 38px 0 22px 0;\n  color: #2e5470;\n}\n.esophaguide-emoji {\n  font-size: 1.2em;\n  vertical-align: middle;\n  margin-right: 3px;\n}\n.esophaguide-section {\n  margin-bottom: 30px;\n  box-shadow: 0 2px 10px 2px #eaeaea33;\n}\n.esophaguide-subtitle {\n  font-size: 1.35rem;\n  font-weight: 600;\n  letter-spacing: 0.015em;\n  margin-bottom: 14px;\n  color: #285581;\n  display: flex;\n  align-items: center;\n}\n.esophaguide-text {\n  font-size: 1.06rem;\n  line-height: 1.72;\n  margin-bottom: 10px;\n  color: #3e4861;\n}\n.esophaguide-tip {\n  color: #345d39;\n  background-color: #ecf9e9;\n  border-radius: 10px;\n  padding: 7px 13px 7px 10px;\n  font-size: 1rem;\n  margin: 10px 0 0 0;\n  border-left: 4px solid #9ccd9c;\n  font-style: italic;\n  display: flex;\n  align-items: center;\n}\n.esophaguide-list {\n  padding-left: 21px;\n  margin-bottom: 10px;\n}\n.esophaguide-list li {\n  margin-bottom: 7px;\n  line-height: 1.5em;\n}\n.esophaguide-example-wrap {\n  padding: 17px 31px 13px 31px;\n  border-radius: 13px;\n  background-color: #f9fbff;\n  margin-bottom: 32px;\n  box-shadow: 0 1px 5px 1px #e7e7f740;\n}\n.esophaguide-example-title {\n  font-size: 1.13rem;\n  font-weight: 600;\n  letter-spacing: 0.01em;\n  color: #325370;\n  margin-bottom: 10px;\n  display: flex;\n  align-items: center;\n}\n.esophaguide-ref-section {\n  background: #f3f4f7;\n  border-radius: 13px;\n  padding: 19px 25px;\n  margin-top: 28px;\n  box-shadow: 0 1px 7px 1px #e2e8ea40;\n}\n.esophaguide-ref-title {\n  font-size: 1.09rem;\n  font-weight: bold;\n  color: #286368;\n  margin-bottom: 7px;\n}\n.esophaguide-ref-list {\n  font-size: 0.97rem;\n  line-height: 1.53;\n  color: #4c505c;\n  padding-left: 19px;\n}\n\u003C/style>\n","\u003Cdiv class=\"esophaguide-wrap\">\n  \u003Ch1 id=\"material_title\" class=\"esophaguide-title\" style=\"color: rgb",379,"2025-07-18 11:47:05","食管腺癌, 药物用药安全, 免疫治疗, 化疗药物, 靶向治疗药物, 不良反应, 药物相互作用, 特殊人群","深入了解食管腺癌治疗药物的用药安全与注意事项，掌握免疫、化疗和靶向药物的应用技巧和不良反应，提升治疗效果并保障患者安全。","2025-07-18 16:24:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]